Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
2.280
-0.010 (-0.44%)
At close: Feb 27, 2026, 4:00 PM EST
2.200
-0.080 (-3.51%)
After-hours: Feb 27, 2026, 7:54 PM EST
Tempest Therapeutics Employees
Tempest Therapeutics had 21 employees as of June 30, 2025. The number of employees decreased by 3 or -12.50% since the number was reported on December 31, 2024.
Employees
21
Change
-3
Growth
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,716,857
Market Cap
30.74M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Kyntra Bio | 225 |
| Passage Bio | 60 |
| Werewolf Therapeutics | 39 |
| Lantern Pharma | 24 |
| AN2 Therapeutics | 22 |
| ABVC BioPharma | 19 |
| NeuroSense Therapeutics | 17 |
| Rallybio | 15 |
TPST News
- 3 days ago - Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - GlobeNewsWire
- 17 days ago - Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - GlobeNewsWire
- 24 days ago - Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - GlobeNewsWire
- 5 weeks ago - Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders - GlobeNewsWire
- 3 months ago - Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 - GlobeNewsWire
- 4 months ago - Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire